top of page
Our Pipeline

Kaerus has leveraged unique mechanistic insights into potassium channel pharmacology to develop proprietary small molecule modulators of the BK (KCa1.1, Slo1, Maxi-K) channels as novel therapeutics for a numerous genetic syndromes.

​

Kaerus' BK Modulator program has been acquired by

image.png

Program

Indication

Preclinical

Phase 1

Phase 2

KER-0193
BK Channel Modulator

Fragile X syndrome

BK Channel Modulator

KCNMA1-linked  Channelopathies

Stage

Preclinical

Preclinical

Preclinical

1884612574 (Lab Scene 2 scientists by microscope)_edited.jpg
Reach out to learn more
Connect with Kaerus to learn more about our company’s targeted therapeutics programs for Fragile X Syndrome and other rare neurodevelopmental disorders. 
bottom of page